223 related articles for article (PubMed ID: 35287626)
1. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
[TBL] [Abstract][Full Text] [Related]
2. Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis.
Wang W; Zou L; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Sun S; Jin M; Zhang F; Hou X; Wei L; Hu K
BMC Cancer; 2021 Jul; 21(1):774. PubMed ID: 34217240
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
[TBL] [Abstract][Full Text] [Related]
4. Practice patterns of adjuvant radiotherapy in women with stage I to II endometrial carcinoma: a real-world multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Womens Health; 2023 Aug; 23(1):417. PubMed ID: 37553639
[TBL] [Abstract][Full Text] [Related]
5. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
[TBL] [Abstract][Full Text] [Related]
6. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Kitchener HC; Lawrie TA
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003916. PubMed ID: 22513918
[TBL] [Abstract][Full Text] [Related]
8. Value of combined adjuvant chemotherapy and radiation on survival for stage III uterine cancer: is less radiation equal to more?
Wang CJ; Christie A; Folkert MR; Xie XJ; Albuquerque K
J Gynecol Oncol; 2018 Jul; 29(4):e49. PubMed ID: 29770620
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Kitchener HC; Lawrie TA
Cochrane Database Syst Rev; 2012 Mar; (3):CD003916. PubMed ID: 22419290
[TBL] [Abstract][Full Text] [Related]
10. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
11. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and radiation therapy modality of younger patients with early-stage endometrial cancer, a multicenter study in China's real world.
Zhang K; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Cancer; 2024 Mar; 24(1):360. PubMed ID: 38509492
[TBL] [Abstract][Full Text] [Related]
13. Vaginal brachytherapy for endometrial cancer.
Hass P; Seinsch S; Eggemann H; Ignatov T; Seitz S; Ignatov A
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1523-1530. PubMed ID: 29730776
[TBL] [Abstract][Full Text] [Related]
14. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
[TBL] [Abstract][Full Text] [Related]
15. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study.
Sorbe B; Horvath G; Andersson H; Boman K; Lundgren C; Pettersson B
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1249-55. PubMed ID: 21676554
[TBL] [Abstract][Full Text] [Related]
16. Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model.
Ren K; Wang W; Sun S; Hou X; Hu K; Zhang F
Cancer Med; 2022 Jan; 11(1):257-267. PubMed ID: 34779587
[TBL] [Abstract][Full Text] [Related]
17. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
[TBL] [Abstract][Full Text] [Related]
18. Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma.
Harkenrider MM; Martin B; Nieto K; Small C; Aref I; Bergman D; Chundury A; Elshaikh MA; Gaffney D; Jhingran A; Lee L; Paydar I; Ra K; Schwarz J; Thorpe C; Viswanathan AN; Small W
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1069-1077. PubMed ID: 29885996
[TBL] [Abstract][Full Text] [Related]
19. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG; Creutzberg CL; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LCHW; van der Steen-Banasik EM; Mens JWM; Slot A; Kroese MCS; van Triest B; Nijman HW; Stelloo E; Bosse T; de Boer SM; van Putten WLJ; Smit VTHBM; Nout RA;
Br J Cancer; 2018 Oct; 119(9):1067-1074. PubMed ID: 30356126
[TBL] [Abstract][Full Text] [Related]
20. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
